
About
CatalYm develops antibodies that will neutralize the tumor-produced immune suppressant GDF-15 to increase immune cell infiltration into the tumor microenvironment, which can also potentiate the activity of (approved) checkpoint-blockers in fighting the tumor.
Focus Areas
["mobility"]
Location
๐ Based in Berlin
Verified Contact & Outreach Agent
Direct Professional Email Pattern
AI Outreach Agent Pitch Writer
Compose an personalized, high-converting outreach message targeting their exact investment interest...